Department of Medical Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Department of Chemistry, University of Science and Technology of China, Hefei, China.
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021 Jan;13(1):e1654. doi: 10.1002/wnan.1654. Epub 2020 Jul 22.
Lung cancer is considered to cause the most cancer-related deaths worldwide. Due to the deficiency in early-stage diagnostics and local invasion or distant metastasis, the first line of treatment for most patients unsuitable for surgery is chemotherapy, targeted therapy or immunotherapy. Nanocarriers with the function of improving drug solubility, in vivo stability, drug distribution in the body, and sustained and targeted delivery, can effectively improve the effect of drug treatment and reduce toxic and side effects, and have been used in clinical treatment for lung cancer and many types of cancers. Here, we review nanoparticle (NP) formulation for lung cancer treatment including liposomes, polymers, and inorganic NPs via systemic and inhaled administration, and highlight the works of overcoming drug resistance and improving cancer immunotherapy. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease.
肺癌被认为是导致全球癌症相关死亡的主要原因。由于早期诊断不足以及局部侵犯或远处转移，大多数不适合手术的患者的一线治疗方法是化疗、靶向治疗或免疫疗法。具有提高药物溶解度、体内稳定性、药物在体内分布以及持续和靶向递送功能的纳米载体，可以有效提高药物治疗效果，降低毒性和副作用，并已用于肺癌和许多类型癌症的临床治疗。在这里，我们通过系统和吸入给药，综述了用于肺癌治疗的纳米颗粒（NP）制剂，包括脂质体、聚合物和无机 NP，并强调了克服药物耐药性和改善癌症免疫治疗的工作。本文属于以下分类：治疗方法和药物发现 > 用于肿瘤疾病的纳米医学。
